Qiagen to ally with Clovis Oncology on lung cancer companion Dx; T2 Biosystems broadens diagnostic detection patents

> Qiagen ($QGEN) will work with Clovis Oncology ($CLVS) on a companion diagnostic that would identify patients who could benefit from an EGFR-targeting lung cancer treatment. Story

> T2 Biosystems, a 2012 FierceMedicalDevices Fierce 15 company, has obtained two additional patents broadening protection for signature diagnostic detection technology behind its T2Candida blood test. Item

> An experimental blood test developed by Integrated Diagnostics has shown promise in detecting early lung cancer well beyond the capacity of scans and invasive biopsies, researchers have concluded. Story

> A molecular diagnostics prototype platform developed by Biocartis in Belgium can detect BRAF mutations in melanoma and other cancer types faster and more accurately than current technology, according to a new study. Item

> Miraca Life Sciences, a company focused on anatomic pathology services, has snatched up PLUS Diagnostics from Water Street Healthcare Partners for an undisclosed price. Item

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.